Cormedix (CRMD) Analyst Rating Update | CRMD Stock News

Author's Avatar
Jun 24, 2025

In recent stock market activity, Needham has maintained its "Buy" rating on Cormedix (CRMD, Financial). Analyst Serge Belanger cited a favorable outlook for the company as reasons for sustaining the positive rating.

Additionally, Needham adjusted its price target for Cormedix (CRMD, Financial), raising it from $15.00 to $20.00. This adjustment represents a 33.33% increase from the prior price target, signaling a bullish sentiment from the analyst community.

Investors in Cormedix (CRMD, Financial) are closely watching these changes, which could potentially impact trading decisions and market performance. The price target increase and consistent "Buy" rating suggest confidence in the company's future growth and potential.

The adjustment comes amid ongoing developments in the company's business strategies and market positioning, making Cormedix (CRMD, Financial) a stock to watch in the coming months.

Needham attributed the price target raise to Cormedix's (CRMD, Financial) continued progress and strategic initiatives that could enhance the company's competitive edge in the industry.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.